These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29676036)

  • 1. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
    Mir Seyed Nazari P; Riedl J; Preusser M; Posch F; Thaler J; Marosi C; Birner P; Ricken G; Hainfellner JA; Pabinger I; Ay C
    J Thromb Haemost; 2018 Jun; 16(6):1121-1127. PubMed ID: 29676036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
    Watanabe J; Natsumeda M; Okada M; Kanemaru Y; Tsukamoto Y; Oishi M; Kakita A; Fujii Y
    World Neurosurg; 2019 Aug; 128():e982-e988. PubMed ID: 31100523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.
    Riedl J; Ay C
    Semin Thromb Hemost; 2019 Jun; 45(4):334-341. PubMed ID: 31041803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.
    Riedl J; Preusser M; Nazari PM; Posch F; Panzer S; Marosi C; Birner P; Thaler J; Brostjan C; Lötsch D; Berger W; Hainfellner JA; Pabinger I; Ay C
    Blood; 2017 Mar; 129(13):1831-1839. PubMed ID: 28073783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
    Burdett KB; Unruh D; Drumm M; Steffens A; Lamano J; Judkins J; Schwartz M; Javier R; Amidei C; Lipp ES; Peters KB; Lai A; Eldred BSC; Heimberger AB; McCortney K; Scholtens DM; Horbinski C
    Blood; 2023 Mar; 141(11):1322-1336. PubMed ID: 36399711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
    Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant IDH1 and thrombosis in gliomas.
    Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
    Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas.
    Ando K; Natsumeda M; Kawamura M; Shirakawa K; Okada M; Tsukamoto Y; Eda T; Watanabe J; Saito S; Takahashi H; Kakita A; Oishi M; Fujii Y
    Thromb Res; 2023 Mar; 223():36-43. PubMed ID: 36706720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.
    Huang Y; Ding H; Luo M; Li S; Xie C; Zhong Y; Li Z
    Support Care Cancer; 2022 Jul; 30(7):6063-6069. PubMed ID: 35419733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
    Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
    Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
    Diaz M; Jo J; Smolkin M; Ratcliffe SJ; Schiff D
    Neurology; 2021 Feb; 96(7):e1063-e1069. PubMed ID: 33361259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
    Chen L; Voronovich Z; Clark K; Hands I; Mannas J; Walsh M; Nikiforova MN; Durbin EB; Weiss H; Horbinski C
    Neuro Oncol; 2014 Nov; 16(11):1478-83. PubMed ID: 24860178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
    Mandel JJ; Youssef M; Yust-Katz S; Patel AJ; Jalali A; Li Z; Wu J; Ludmir EB; de Groot JF
    J Neurol Sci; 2021 Aug; 427():117538. PubMed ID: 34146775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application.
    Aibaidula A; Zhao W; Wu JS; Chen H; Shi ZF; Zheng LL; Mao Y; Zhou LF; Sui GD
    J Neurosurg; 2016 Jun; 124(6):1611-8. PubMed ID: 26544771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.
    Low SK; Anjum Z; Mahmoud A; Joshi U; Kouides P
    Thromb Res; 2022 Nov; 219():14-21. PubMed ID: 36088710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
    Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
    Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.